Drug Trial Radar · NCT04752540
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
Last checked: Nov 19, 2026Latest source record: Mar 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jul 2, 2021
Primary completion
Oct 24, 2021
Study completion Oct 24, 2021
Sponsor
- Lead sponsor
- F2G Biotech GmbHIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single oral dose study to investigate the PK and safety of olorofim in mild and moderately hepatically impaired subjects compared to subjects with normal hepatic function.
Conditions
- Hepatic Impairment
Interventions
OlorofimDrug
single oral dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-Time Curve From Time Zero to the time of the last quantifiable concentration (AUC 0-t)Time frame: 0-96 hours
- Maximum Observed Plasma Concentration (Cmax)Time frame: 0-96 hours
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Orange County Research Centre
Tustin, California
Orlando Clinical Research Centre
Orlando, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.